ReviewInternational journal of nanomedicine2025
Innovative Applications of Nucleic Acid Aptamers in Colorectal Cancer Diagnosis and Therapy: From Selection Optimization to Clinical Translation.
Review in International journal of nanomedicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Aqueous Artemisia argyi extract mitigates acute lung injuryFrontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC), a gastrointestinal malignancy with persistently high global incidence and mortality rates, urgently demands more efficient early screening strategies and precision therapeutic approaches. Nucleic acid aptamers, recognized as "chemical antibodies", have emerged as a research hotspot in CRC diagnosis and treatment due to their high target specificity, flexible chemical modifiability, and cost-effective synthesis. In diagnostic applications, integrating aptamers with fluorescence, surface-enhanced Raman scattering (SERS), and electrochemical biosensors, along with functionalized nanomaterials such as quantum dots, gold nanoparticles, and graphene, has enabled ultrasensitive detection of biomarkers including carcinoembryonic antigen (CEA), miRNAs, exosomes, and circulating tumor cells (CTCs). In the therapeutic arena, we highlight aptamer-decorated lipidic, polymeric, and inorganic nanocarrier systems for targeted drug delivery featuring pH/glutathione (GSH)-responsive release mechanisms, and we review emerging immunotherapeutic regimens that employ PD-1/PD-L1 blocking aptamers alone or in combination with immunomodulatory agents or small activating RNAs. Finally, current challenges in aptamer applications-such as in vivo stability, targeted delivery efficiency, large-scale production, and clinical translation-are critically discussed. Future perspectives propose AI-assisted intelligent aptamer design, multi-omics-integrated diagnostic and therapeutic platforms, and standardized clinical trials to advance the implementation of nucleic acid aptamers in CRC precision medicine.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.